Latest News

MS treatment recommendations during COVID-19 pandemic


The Canadian Network of MS Clinics has posted a Q&A for patients with multiple sclerosis. Included are the group’s recommendations (see link below) for disease-modifying therapies (DMTs). Not immunosuppressant: Beta-interferons (Avonex, Betaseron/Extavia, Rebif, Plegridy), glatiramer acetate (Copaxone, Glatect), teriflunomide (Aubagio), and minocycline. Read More

MS 2020 – the view from a decade ago


“It’s difficult to make predictions – especially about the future.” – Yogi Berra

A decade ago, Dr. Aaron Miller, Mount Sinai, New York, took a game swing at the crystal ball and wrote the article, “Multiple sclerosis: where will we be in 2020?” (Miller A. Mt Sinai J Med 2011;78:268-279). Read More


Evaluating acute migraine therapies: ICER


The Institute for Clinical and Economic Review (ICER), a drug pricing watchdog in the U.S., has ruled that novel oral migraine therapies have similar effectiveness but are not superior to triptans (5-HT 1B/1D agonists). Read More